Adjuvant Quil A improves protection in mice and enhances opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines

Vaccine
E A DeVelascoHarm Snippe

Abstract

The adjuvant effect of Quil A on the primary antibody response of mice to pneumococcal capsular polysaccharide conjugates was examined. Quil A increased the anti-capsular polysaccharide antibody titres, the protection against Streptococcus pneumoniae, and the opsonic capacity of the antibodies as measured in a newly developed in vitro phagocytosis assay, using the mouse macrophage cell line J774.

References

Sep 22, 2010·Marine Biotechnology·Jun Zhang, Shicui Zhang
Aug 2, 2016·Comparative Immunology, Microbiology and Infectious Diseases·Lidia Gómez-GascónInmaculada Luque
Jun 15, 2007·Clinical and Vaccine Immunology : CVI·Yuanyi LiJosee Harel
May 1, 2001·Clinical and Diagnostic Laboratory Immunology·J S LinM H Nahm

Related Concepts

Saponin
Mice, Inbred BALB C
Immunologic Adjuvants
Adjuvant
Quil A
Antibody Titer Measurement
Immune Sera
Vaccines, Conjugate
Antibody Formation
Opsonin

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.